Herein we report the case of a young man, admitted to the Department of Cardiology and Angiology at Hannover Medical School with shortness of breath and elevated troponin. Few weeks earlier the patient received the first dose of BioNTech's mRNA vaccine (Comirnaty, BNT162b2). After diagnostic work-up revealed giant cell myocarditis, the patient received immunosuppressive therapy. In the present context of myocarditis after mRNA vaccination we discuss this rare aetiology and the patient's treatment strategy in the light of current recommendations.

中文翻译：

---

首剂 BNT162b2 后巨细胞心肌炎 – 病例报告

在此，我们报告了一名因呼吸急促和肌钙蛋白升高而被汉诺威医学院心脏病学和血管学系录取的年轻人的病例。几周前，患者接受了第一剂 BioNTech 的 mRNA 疫苗（Comirnaty，BNT162b2）。诊断检查发现巨细胞心肌炎后，患者接受了免疫抑制治疗。在目前 mRNA 疫苗接种后心肌炎的背景下，我们根据当前的建议讨论这种罕见的病因和患者的治疗策略。